EUVIMEDEUVIMED entdecken
Kontrollierte klinische StudieStudienprotokoll

Treatment protocol for medication-related osteonecrosis of the jaws: stages I and II-based on a pharmacological and surgical scheme

Nicolás Leonardi, Gerardo Gilligan, Eduardo David Piemonte, Rene Luis Panico

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology · 2025

DOI: 10.1016/j.oooo.2025.11.009 ↗

Kurz gefasst

Kontrollierte klinische Studie in der Zeitschrift Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2025. Verfasst von Nicolás Leonardi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oral Medicine Department, Dentistry School, Facultad de Ciencias de la Salud, Universidad Católica de Córdoba, Córdoba, Argentina. Electronic address…. Hauptthemen laut MEDLINE: Pentoxifylline, Bisphosphonate-Associated Osteonecrosis of the Jaw, Platelet-Rich Fibrin, Tocopherols. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Medication-related osteonecrosis of the jaws (MRONJ) is a complex oral condition for which no global consensus on management currently exists, underscoring the need to establish internationally accepted therapeutic protocols. The use of platelet-rich fibrin (PRF) and the adjunctive administration of pentoxifylline and tocopherol (PenTo) have shown promising preliminary results in the clinical management of MRONJ; however, robust data remain limited. The aim of this study is to analyze the outcomes of surgically treated patients with stage I and II MRONJ, incorporating PenTo as an adjuvant to platelet concentrate therapy. Furthermore, the study seeks to evaluate both clinical and radiographic outcome variables throughout the follow-up period. METHODS: A controlled pharmacological clinical trial was conducted, using a standard drug regimen as the comparator. Total 20 patients diagnosed with stage I or II MRONJ were allocated into 2 groups: one group received surgical treatment combined with PRF, while the other underwent the same protocol supplemented with an adjuvant therapeutic regimen based on PenTo. Participants were recruited from the Oral Medicine Department, School of Dentistry, Universidad Católica de Córdoba. RESULTS: Statistically significant differences were observed in the mean duration of antiresorptive therapy, which was notably longer in patients with osteoporosis (P = .01). Zoledronic acid was the most frequently associated drug (P = .0019). The addition of PenTo to the treatment protocol was associated with improved clinical and radiographic outcomes, with statistically significant differences (P = .0138 and P = .0046, respectively). Furthermore, the diagnostic stage (I or II) showed a significant correlation with clinical improvement following treatment (P = .0294). The healing index at 15, 90, and 180 days was higher in the group receiving PenTo, with statistically significant differences at each time point (P = .0441; P = .0001; P = .0018, respectively). In oncological patients, the healing index was also higher at all follow-up stages, with clear statistical significance (P = .0294; P = .0004; P = .0042). CONCLUSIONS: This study contributes with patient-based evidence to support the interdisciplinary management of MRONJ. The combination of surgical treatment, PRF, and PenTo may serve to optimize and enhance clinical strategies for this condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PentoxifyllineBisphosphonate-Associated Osteonecrosis of the JawPlatelet-Rich FibrinTocopherolsHumansFemaleMaleAgedMiddle AgedTreatment OutcomeCombined Modality TherapyZoledronic AcidBone Density Conservation AgentsClinical Protocols

Substanzen

PentoxifyllineTocopherolsZoledronic AcidBone Density Conservation Agents

Autor:innen und Institutionen

  • Oral Medicine Department, Dentistry School, Facultad de Ciencias de la Salud, Universidad Católica de Córdoba, Córdoba, Argentina. Electronic address: nico_leonardi@hotmail.com.ar.
  • Oral Medicine Department, Facultad de Odontología, Universidad Nacional de Córdoba, Córdoba, Argentina.
  • Oral Medicine Department, Dentistry School, Facultad de Ciencias de la Salud, Universidad Católica de Córdoba, Córdoba, Argentina; Oral Medicine Department, Facultad de Odontología, Universidad Nacional de Córdoba, Córd…

Zitieren

APA

Leonardi, N., Gilligan, G., Piemonte, E. D., & Panico, R. L. (2025). Treatment protocol for medication-related osteonecrosis of the jaws: stages I and II-based on a pharmacological and surgical scheme. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. https://doi.org/10.1016/j.oooo.2025.11.009

Vancouver

Leonardi N, Gilligan G, Piemonte ED, Panico RL. Treatment protocol for medication-related osteonecrosis of the jaws: stages I and II-based on a pharmacological and surgical scheme. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2025. doi:10.1016/j.oooo.2025.11.009

BibTeX
@article{Leonardi2025,
  author = {Leonardi, Nicolás and Gilligan, Gerardo and Piemonte, Eduardo David and Panico, Rene Luis},
  title = {Treatment protocol for medication-related osteonecrosis of the jaws: stages I and II-based on a pharmacological and surgical scheme},
  journal = {Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology},
  year = {2025},
  doi = {10.1016/j.oooo.2025.11.009}
}
Kostenlos starten →